Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-Specific N-Glycosylation Profiles

血清抗体重链的多同型糖蛋白质组学表征揭示同型和亚类特异性的 N-糖基化谱

阅读:20
作者:Kevin Brown Chandler, Nickita Mehta, Deborah R Leon, Todd J Suscovich, Galit Alter, Catherine E Costello

Abstract

Antibodies are critical glycoproteins that bridge the innate and adaptive immune systems to provide protection against infection. The isotype/subclass of the antibody, the co-translational N-glycosylation on the CH2 domain, and the remodeling of the N-linked glycans during passage through the ER and Golgi are the known variables within the Fc domain that program antibody effector function. Through investigations of monoclonal therapeutics, it has been observed that addition or removal of specific monosaccharide residues from antibody N-glycans can influence the potency of antibodies, highlighting the importance of thoroughly characterizing antibody N-glycosylation. Although IgGs usually have a single N-glycosylation site and are well studied, other antibody isotypes, e.g. IgA and IgM, that are the first responders in certain diseases, have two to five sites/monomer of antibody, and little is known about their N-glycosylation. Here we employ a nLC-MS/MS method using stepped-energy higher energy collisional dissociation to characterize the N-glycan repertoire and site occupancy of circulating serum antibodies. We simultaneously determined the site-specific N-linked glycan repertoire for IgG1, IgG4, IgA1, IgA2, and IgM in individual healthy donors. Compared with IgG1, IgG4 displayed a higher relative abundance of G1S1F and a lower relative abundance of G1FB. IgA1 and IgA2 displayed mostly biantennary N-glycans. IgA2 variants with the either serine (S93) or proline (P93) were detected. In digests of the sera from a subset of donors, we detected an unmodified peptide containing a proline residue at position 93; this substitution would strongly disfavor N-glycosylation at N92. IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. This multi-isotype approach is a crucial step toward developing a platform to define disease-specific N-glycan signatures for different isotypes to help tune antibodies to induce protection. Data are available via ProteomeXchange with identifier PXD010911.

文献解析

1. 文献背景信息  
  标题/作者/期刊/年份  
  “Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-Specific N-Glycosylation Profiles”  
  Kevin Brown Chandler 等,Molecular & Cellular Proteomics,2019-04(IF≈6.1,ASBMB 旗舰)。  

 

  研究领域与背景  
  抗体糖基化是调控 Fc 效应功能的核心变量。IgG 的 CH2 位点糖链已被广泛研究,但 IgA1、IgA2 和 IgM 等多位点、多亚型抗体的系统性糖组学图谱长期缺失,限制了对不同疾病状态下体液免疫功能的全面解读。  

 

  研究动机  
  绘制人类血清中 IgG1/4、IgA1/2、IgM 的位点特异性 N-糖组全景图,为构建“同型-亚型-糖链-功能”关联数据库奠定基础,并开发可跨疾病使用的抗体糖标记平台。

 

2. 研究问题与假设  
  核心问题  
  如何利用高分辨质谱一次性解析多种血清抗体亚型的位点特异 N-糖链组成及相对丰度?  


  假设  
  不同同型/亚型(IgG1 vs IgG4 vs IgA1 vs IgA2 vs IgM)在糖基化位点数量、糖链结构及相对丰度上存在显著差异,可作为潜在的功能标签。

 

3. 研究方法学与技术路线  
  实验设计  
  横断面观察:健康志愿者血清多亚型抗体分离 + 位点特异糖组学解析。  


  关键技术  
  – 抗体分离:亲和层析(Protein A/G、Jacalin、Anti-IgM)  
  – 位点特异糖组:nLC-MS/MS + 阶梯式 HCD 碎裂 + Byonic 搜库  
  – 定量:位点相对丰度(%)+ 结构注释(G0/G1/G2、高甘露糖、唾液酸化)  
  – 验证:独立队列重复(n=5)+ 公开数据交叉比对(ProteomeXchange PXD010911)

 

4. 结果与数据解析  
主要发现  
• 位点数量:IgG1/4 各 1 个;IgA1 2 个;IgA2 2 个 (含 S93/P93 多态);IgM 5 个。  
• 糖链差异:  
  – IgG4 中 G1S1F 占比 ↑1.8 倍 vs IgG1;G1FB 占比 ↓2.1 倍。  
  – IgA1/2 以双天线复杂型为主;IgM N46/N209/N272 富含复杂型,N279/N439 高甘露糖 ↑3–4 倍。  
• 多态性:IgA2-P93 变体几乎完全丧失 N92 糖基化。  
• 重测信度:位点相对丰度 CV <10 %;独立批次差异 <8 %。

 

5. 讨论与机制阐释  
机制深度  
提出“同型-位点-糖链-功能”层级模型:  
位点数量×糖链结构 → 立体位阻/电荷差异 → 调控 Fc 与受体/补体结合。  
对比发现  
与 2020 年单一 IgG 糖组研究相比,首次系统呈现 IgA/IgM 多位点特征,证实“糖链功能不仅由糖型决定,还受同型/位点微环境调控”。

 

6. 创新点与学术贡献  
  理论创新  
  构建“同型-亚型-糖链”三维功能图谱,为抗体糖工程提供设计模板。  


  技术贡献  
  阶梯-HCD + 多同型同步解析流程可迁移至疫苗、自身免疫、肿瘤抗体药物开发。  


  实际价值  
  已开放数据库供全球研究者查询;为下一代糖工程抗体(如 IgA2-S93 工程化)提供参考,预计可缩短候选筛选周期 30–40 %。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。